Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 1/2 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Stomach Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Skin Neoplasms 1Sarcoma, Ewing 1Radiation Injuries 1Postoperative Complications 1Pilonidal Sinus 1Osteosarcoma 1Neoplasms 1Lymphatic Metastasis 1Low Anterior Resection Syndrome 1Gestational Trophoblastic Disease 1Fatigue 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 8Radiotherapy 6Fluorouracil 4Paclitaxel 3tislelizumab 2nimotuzumab 2Neoadjuvant Therapy 2Esophagectomy 2Drug Therapy 2Capecitabine 2spartalizumab 1pembrolizumab 1anlotinib 1TP protocol 1Surgical Procedures, Operative 1Radiation 1Oxaliplatin 1Nivolumab 1Leucovorin 1Immunotherapy 1Docetaxel 1Clinical Trials, Phase II as Topic 1Chemoradiotherapy 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Esophageal Squamous Cell Carcinoma × Surgical Procedures, Operative × Clear all
NCT02272699 2021-03-18

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma

Peking University

Phase 2/3 Withdrawn
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡